Autres langues Galectin Therapeutics Inc.

Actions

GALT

US3632252025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
3,45 ^USD	-1,43%		+2,37%	+107,83%

29/03	Galectin Therapeutics Inc. nomme Benjamin S. Carson membre du conseil d'administration	CI
29/03	Galectin Therapeutics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Galectin Therapeutics : Corporate Presentation, April 2024	17/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	10/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	09/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	01/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	29/03
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	29/03
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	29/03
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
North American Morning Briefing : Stocks Set for -2-	28/03
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	12/03
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	13/11
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
North American Morning Briefing : Stock Futures -2-	13/11
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	03/11
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23/10/23
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	12/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	04/10/23
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	03/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	03/10/23
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	03/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Galectin Therapeutics Inc.

Actions

GALT

US3632252025

Autres langues

Filtres